Back to Results
First PageMeta Content
Private equity / Venture capital / Biomax Informatics AG / MorphoSys / Financial economics / Finance / Investment


Microsoft Word - 041011_PM_Biomax_Investment_e.doc
Add to Reading List

Document Date: 2014-04-07 18:55:59

Open Document

File Size: 169,56 KB

Share Result on Facebook

City

Martinsried / Munich / /

Company

MorphoSys / BayBG Beteiligungsgesellschaft mbH / BayBG Bayerische Beteiligungsgesellschaft mbH / Biomax Informatics AG / Roche Diagnostics / ECOS Venture Capital Beteiligungs AG / DSM / QIAGEN / Schering / S-UBG Bayern / Cold Spring Harbor Laboratory / BASF / Unternehmensbeteiligungen AG / /

Country

Germany / Netherlands / Austria / United States / /

Currency

EUR / /

/

Event

Funding / /

Facility

National Cancer Institute / /

IndustryTerm

venture capital / biotechnology / mezzanine investment products / universal venture capital / pharmaceutical / high-tech investments / venture capital technology funds / research / savings banks / technology / venture capital consortium / bioinformatics tools / bioinformatics solutions / spin-off / /

OperatingSystem

ECOS / /

Organization

National Cancer Institute / Institute for Bioinformatics / German Research Center for Environment / /

Person

Klaus Heumann / Frank Zimmerman / D. Frishman / Wolf Rüdiger Willig / H. W. Mewes / K. Heumann / Hans-Jürgen Schmitz / Hein Paul Osenberg / /

/

Position

executive officer / CEO and founder / investment manager / CFO / leader in the development / /

ProvinceOrState

Bavaria / /

Technology

proteomics / bioinformatics / information technologies / biotechnology / gene expression / /

URL

www.baybg.de / www.subg-bayern.de / www.ecosventure.at / www.biomax.com / /

SocialTag